<DOC>
	<DOCNO>NCT00637572</DOCNO>
	<brief_summary>Explore weight gain HIV-positive patient weight loss associate AIDS-related wasting ( anorexia/cachexia ) . Patients treat 12 week either megestrol acetate oral suspension nanocrystal dispersion formulation , megestrol acetate oral suspension original formulation</brief_summary>
	<brief_title>Evaluate Weight Gain Using 2 Different Formulations Megestrol Acetate Oral Suspension AIDS-related Weight Loss</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Wasting Syndrome</mesh_term>
	<mesh_term>HIV Wasting Syndrome</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Capable willing provide inform consent Evidence HIV infection ( either HIVseropositive , CD4+ Tcell count â‰¤350/mm3 clinically accept indicator ) An unintentional weight loss result weight 10 % less low limit Ideal Body Weight frame size , recent history unintentional weight loss 10 % subject baseline Weight loss clinically associate AIDSrelated waste related disease process Women childbearing potential agree use effective contraception duration study two week last dose Clinical laboratory value within normal limit outofrange limit must designate clinically significant ( exception per protocol ) Able read write study related document translate primary local language Capable willing return clinic regularly study visit Must take stable regimen accept HIV antiretroviral treatment least two week prior study entry Capable complete 3day food intake diary instruction Willing abstain illegal recreational drug substance duration trial Willing abstain take medication substance know affect appetite weight gain ( eg , steroid [ inhaled treatment asthmatic condition ] , nutritional supplement [ vitamin mineral ] , dronabinol , recombinant human growth hormone , etc . ) Weight loss due factor AIDSrelated waste Enrollment clinical trial Lack access regular meal Women childbearing potential could pregnant nurse Clinically severe depression evidence baseline score 17 Hamilton Depression Rating Scale ( GRIDHAMD17 ) Recent evidence history significant psychiatric illness may compromise subject 's ability comply study requirement Intractable frequent vomit regularly interfere eat Clinically significant diarrhea would interfere absorption food medication Clinically significant oral lesion dental condition would interfere eat regular diet History evidence thromboembolic event first degree relative history thromboembolic event Active AIDSdefining illness clinically significant uncontrolled medical problem Current evidence history diabetes mellitus hypoadrenalism Systemic treatment glucocorticoid within 12 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Weight loss</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Anorexia</keyword>
	<keyword>Megestrol acetate oral suspension</keyword>
	<keyword>Nanocrystal dispersion</keyword>
	<keyword>Nanocrystal technology</keyword>
	<keyword>Body weight change</keyword>
	<keyword>AIDS wasting</keyword>
	<keyword>HIV wasting</keyword>
	<keyword>Emaciation</keyword>
	<keyword>Megace ES</keyword>
	<keyword>Megace</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>